Planet MicroCap posted a video interview with Jim Martin, Co-CEO and CFO of Cocrystal Pharma (NASDAQ:COCP), a clinical-stage biotechnology company. Martin discusses Cocrystal’s antiviral therapeutics’ clinical development and 2024 outlook.
The company has a market cap of $15.53 million and has been trading for the last month at the lower end of its 52-week range ($3.28 – $1.32).
Cocrystal Pharma is discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2) noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs.
DealFlow Events makes no recommendations on whether to buy, sell or hold shares of any particular stock. Investors are advised to conduct their own research and analysis before making an investment decision. Neither DealFlow Events nor any of its affiliates hold any position in the stocks mentioned in The Microcap Newsletter. Watch the interview.
